Oncology

pharma-news-for-astrazeneca-argenx-bristol-myers-squibb

Notizia - Recent Pharma, Healthcare and Biotech Happenings

AstraZeneca Discontinues Phase III eVOLVE-Lung02 Trial of Volrustomig in Metastatic NSCLC; argenx Announces Favorable Topline Results from Phase 3 ALKIVIA Study of Efgartigimod; Bristol Myers Squibb’s ZENBEXUS Receives U.S. FDA Accelerated Approval in Combination with Daratumumab and Dexamethasone for Multiple Myeloma; Zealand Pharma Secures USD 100 Million in Royalty Financing Through Agreement with Royalty Pharma for Rusfertide; PTC Advances Rare Disease Strategy with Acquisition of ST-920 Fabry Disease Program

Explore More...
kras-inhibitors-beyond-g12c

Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C

pd-1-inhibitors-by-companies

PD-1 Inhibitors: Which Companies Are Winning the Immunotherapy Race?

liquid-biopsy-revolutionary-technique-for-cancer-diagnosis

Liquid Biopsy: The Blood Test That Is Redefining Cancer Diagnosis, Monitoring, And Precision Oncology

regenerative-medicine-revolution

The Regenerative Medicine Revolution: Opportunities Shaping the Next Decade

sanofi-sarclisa-escena-approval

Sanofi’s SARCLISA ESCENA Makes History as the First Wearable Cancer Treatment

drug-approvals-in-h2-2026

Top FDA Approvals to Watch in H2 2026: Regulatory Decisions Poised to Transform the Pharmaceutical Landscape

rise-of-targeted-therapeutics

The Rise of Targeted Therapeutics in Modern Healthcare

pharma-news-for-hengrui-kailera-gsk

Hengrui Pharma Encounters FDA Regulatory Hurdle for Camrelizumab–Rivoceranib; Kailera Therapeutics Announces Positive Results for HRS-7535/KAI-7535 Across Two Phase 3 Studies; Jemperli Underscores Durable Clinical Complete Responses in dMMR/MSI-H Rectal Cancer; FDA Approves PADCEV-Keytruda Combination for Neoadjuvant and Adjuvant Treatment of Muscle-Invasive Bladder Cancer; Sanofi’s Subcutaneous Sarclisa Escena Gains US Approval

pharma-news-for-novartis-roche-otsuka

Novartis to Acquire Myricx Bio; Roche’s Divarasib Tops Approved KRAS G12C Inhibitors in Phase III NSCLC Trial; Otsuka Reports Positive Two-Year Phase 3 Results for VOYXACT in IgA Nephropathy; Revolution Medicines Reports Early Clinical Data for Zoldonrasib Combination Regimens at ESMO GI 2026; Can-Fite Completes Patient Enrolment for Interim Analysis in Pivotal Phase 3 Psoriasis Trial

pcpg-therapeutic-landscape

Paragangliomas and Pheochromocytomas Treatment Space Steps into the Precision Therapy Era

progeria-causes-symptoms-risk-factors-and-treatment-options

Progeria Syndrome: The Rarest Case of Premature Ageing

pharma-news-for-zymeworks-ipsen-viridian-assessment

Zymeworks Announces Acquisition of Theravance Biopharma; Ipsen to Acquire Kartos Therapeutics; Viridian Therapeutics Wins U.S. FDA Approval for Lumvoa; Replimune Reaches FDA Milestone with RP1 BLA Resubmission Acceptance; Epicrispr Announces Encouraging Clinical Data for EPI-321 in FSHD

trodelvy-approval-for-mtnbc

TRODELVY’s First-Line TNBC Approval: Gilead’s Big Bet Reshapes the TROP2 ADC Battlefield

role-of-fusion-biopsy-in-prostate-cancer-detection

Fusion Biopsy: The Next Generation of Prostate Cancer Detection

next-frontier-in-egfr-mutant-nsclc-treatment

EGFR-Mutant NSCLC: From Targeted Therapy Breakthroughs to the Next Era of Precision Medicine

evolution-of-biliary-tract-cancer-treatment

Navigating the Future of Biliary Tract Cancer Treatment: Precision Oncology and Emerging Therapeutic Strategies

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader